Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology · 2026-07 · 183 (14) · 3970-3991
DOI: 10.1111/bph.17370 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-10-28. Written by Laith Alexander and 5 co-authors. Institution: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Major MEDLINE topics: Hallucinogens, Major Depressive Disorder, Antidepressive Agents. Cited 11 times so far (Crossref); 210 references. The full text is freely available (open access, CC BY 4.0). Funded by: Biotechnology and Biological Sciences Research Council, National Institute for Health Research (NIHR) Biomedical Research Centre, National Institute for Health Research (NIHR).
Abstract (original language)
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood. For example, key questions such as whether antidepressant and psychedelic effects involve related or independent mechanisms are unresolved. Preclinical studies in relevant animal models are key to understanding the pharmacology of psychedelics and translating these findings to explain efficacy and safety in patients. Understanding the mechanisms of action associated with the behavioural effects of psychedelic drugs can also support the identification of novel drug targets and more effective treatments. Here we review the behavioural approaches currently used to quantify the psychedelic and antidepressant effects of psychedelic drugs. We discuss conceptual and methodological issues, the importance of using clinically relevant doses and the need to consider possible sex differences in preclinical psychedelic studies. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- South London and the Maudsley NHS Foundation Trust, London, UK.
- School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.
ORCID profiles: Emma S J Robinson
Funding
- Biotechnology and Biological Sciences Research Council
- National Institute for Health Research (NIHR) Biomedical Research Centre
- National Institute for Health Research (NIHR)
- Wellcome Trust
- NIHR Academic Clinical Fellowship
- National Institute for Health and Care Research
- NIHR Cambridge Biomedical Research Centre
Cite
APA
Alexander, L., Anderson, D., Baxter, L., Claydon, M., Rucker, J., & Robinson, E. S. J. (2026). Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology, 183(14), 3970-3991. https://doi.org/10.1111/bph.17370
Vancouver
Alexander L, Anderson D, Baxter L, Claydon M, Rucker J, Robinson ESJ. Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology. 2026;183(14):3970-3991. doi:10.1111/bph.17370
BibTeX
@article{Alexander2026,
author = {Alexander, Laith and Anderson, Dasha and Baxter, Luke and Claydon, Matthew and Rucker, James and Robinson, Emma S J},
title = {Preclinical models for evaluating psychedelics in the treatment of major depressive disorder},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {14},
pages = {3970--3991},
doi = {10.1111/bph.17370}
}
EUVIMED